Back to today’s briefing

Story perspectives

FDA Rejects Eight Experimental Drugs, Sparking Market Uncertainty

3/7/2026

32 7 Full Breakdown

Summary

Story summary

The U.S. Food and Drug Administration has rejected at least eight experimental drugs for hard-to-treat diseases over the past year.
The rejections reflect issues with the evidence companies provided and have created market uncertainty.
UniQure and Denali Therapeutics face challenges meeting the FDA's evolving standards amid the scrutiny.
The FDA maintains biomarker data can support accelerated approvals, though investor skepticism remains.

1 of 1

Story summary

The U.S. Food and Drug Administration has rejected at least eight experimental drugs for hard-to-treat diseases over the past year.
The rejections reflect issues with the evidence companies provided and have created market uncertainty.
UniQure and Denali Therapeutics face challenges meeting the FDA's evolving standards amid the scrutiny.
The FDA maintains biomarker data can support accelerated approvals, though investor skepticism remains.